Materiały źródłowe

• #1 Zollinger-Ellison Syndrome – NIDDK

  https://www.niddk.nih.gov/health-information/digestive-diseases/zollinger-ellison-syndrome

  Zollinger-Ellison syndrome is rare. Only 0.5 to 3 out of every 1 million people are diagnosed with Zollinger-Ellison syndrome each year. […] Zollinger-Ellison syndrome is slightly more common in men than in women. […] About 80% of cases of Zollinger-Ellison syndrome is unrelated to other conditions, but 20% to 25% of cases occur in people who have a rare, genetic disorder called multiple endocrine neoplasia type 1 (MEN1). […] The extra stomach acid caused by Zollinger-Ellison syndrome can lead to peptic ulcer disease or GERD. […] The tumors that cause Zollinger-Ellison syndrome are sometimes cancerous and may spread to other parts of your body. […] In about 20% to 25% of cases, a rare genetic disorder called MEN1 causes gastrinomas to form. […] If your doctor suspects you may have Zollinger-Ellison syndrome, he or she will order tests to diagnose this condition.

• #1 Zollinger-Ellison Syndrome – NIDDK

  https://www.niddk.nih.gov/health-information/digestive-diseases/zollinger-ellison-syndrome

  Doctors may order imaging tests to help find the tumors that cause Zollinger-Ellison syndrome. […] Doctors treat Zollinger-Ellison syndrome with medicines and surgery. […] Treating Zollinger-Ellison syndrome reduces the amount of acid in the stomach, which can help prevent or treat complications related to peptic ulcers or acid reflux. […] Researchers are studying many aspects of Zollinger-Ellison syndrome, including improved ways to diagnose and treat this condition.

• #2 Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis – UpToDate

  https://www.uptodate.com/contents/zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis/print

  Zollinger-Ellison syndrome (ZES) is caused by secretion of gastrin by duodenal or pancreatic neuroendocrine tumors (gastrinomas). The annual incidence of gastrinomas is 0.5 to 2 per million population. Most patients are diagnosed between the ages of 20 and 50, with a higher incidence in males as compared with females. Approximately 80 percent of gastrinomas are sporadic, but 20 to 30 percent occur in association with multiple endocrine neoplasia type 1 (MEN1). […] Although gastrinomas are one of the most common functional pancreatic neuroendocrine tumors, only 20 to 25 percent of gastrinomas arise in the pancreas. Approximately 50 to 88 percent of patients with sporadic ZES, and 70 to 100 percent of patients with ZES associated with MEN1, have duodenal gastrinomas. Duodenal gastrinomas are predominantly found in the first part of the duodenum. As compared with pancreatic gastrinomas, duodenal gastrinomas are usually small (<1 cm), are often multiple, and are less likely to have metastasized to the liver at diagnosis (0 to 10 versus 22 to 35 percent). In 5 to 15 percent of patients, gastrinomas arise in non-pancreatic, non-duodenal abdominal (stomach, peripancreatic lymph nodes, liver, bile duct, ovary), and extra-abdominal (heart, small cell lung cancer) locations.

• #3 Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome – PubMed

  https://pubmed.ncbi.nlm.nih.gov/22902777/

  Zollinger-Ellison syndrome (ZES) is a rare disorder characterized by gastrin-secreting tumors of the gastrointestinal tract and gastric acid hypersecretion. […] We performed a retrospective chart review of patients with ZES associated with multiple endocrine neoplasia type 1 (MEN-1) (n = 16) and those with sporadic ZES (n = 33) seen at a tertiary care center from August 1994 to January 2012. […] Patients with MEN-1 syndrome-associated ZES presented at a younger age than patients with sporadic ZES (34.9 vs 45.7 y, respectively; P .05) and were diagnosed at a younger age (39.3 vs 49.7 y, respectively; P .01), yet lived a similar number of years (55.9 vs 55.1 y, respectively; P = .91). […] None of the patients with MEN-1-associated ZES died of progressive disease, compared with 86% of deaths among patients with sporadic ZES (P .05).

• #3 Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome – PubMed

  https://pubmed.ncbi.nlm.nih.gov/22902777/

  Surgery reduced all-cause mortality (hazard ratio, 0.11; 95% confidence interval, 0.2-0.6; P = .011) and disease-related mortality (hazard ratio, 0.14; 95% confidence interval, 0.2-0.84; P = .032) of patients with sporadic, but not MEN-1 syndrome-associated, ZES. […] The presence of MEN-1 is associated with earlier onset and diagnosis of ZES, but a benign clinical course that rarely results in disease-related death; surgery therefore can be deferred for these patients. […] However, 86% of deaths among patients with sporadic ZES are attributed to disease-related causes, and mortality is reduced by early surgical intervention. Patients with sporadic ZES should undergo surgery soon after diagnosis.

• #4 Zollinger-Ellison Syndrome: Symptoms and Treatment

  https://patient.info/doctor/zollinger-ellison-syndrome

  The incidence of Zollinger-Ellison syndrome is rare, ranging from is 0.1-3/million population/year. […] 20-30% of patients have ZES as part of MEN1, an autosomal dominant disorder. […] Mean age of presentation is around 40, being younger in MEN1 patients than sporadic cases. Only about 3% present before age 20 and 7% after age 60. […] Gastrinomas are the most common functioning tumour of the pancreas. In addition to secreting high levels of gastrin, these tumours may produce other hormones such as adrenocorticotrophic hormone (ACTH), vasoactive intestinal polypeptide (VIP), and glucagon. […] It has been argued that the widespread use of PPIs may delay the diagnosis of ZES so that presentation is later and more advanced.

• #5 Zollinger-Ellison Syndrome: Background, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/183555-overview

  Zollinger-Ellison syndrome (ZES) occurs in approximately 0.1-1% of all patients with duodenal ulcers. Its frequency of occurrence is reported to be approximately the same as insulinoma, the most common functioning pancreatic endocrine tumor. […] A slight male predominance exists, with a male-to-female ratio of 1.3:1. […] The mean age of onset of ZES is 43 years; however, patients with multiple endocrine neoplasia-type 1 and ZES (MEN 1/ZES) present a decade earlier. Generally, a 5- to 7-year delay in diagnosis occurs. In a prospective study, fewer than 3% of patients were younger than 20 years, whereas 7% were older than 60 years at the time of disease onset. […] Incidence is 1-3 cases per million patients per year in Sweden, 0.5 cases per million patients per year in Ireland, and 0.1-0.2 cases per million patients per year in Denmark.

• #6 Zollinger–Ellison syndrome – Wikipedia

  https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome

  The condition most commonly affects people between the ages of 30 and 60. The prevalence is unknown, but estimated to be about 1 in 100,000 people.

• #7 Zollinger-Ellison Syndrome: Symptoms, Treatment, and More

  https://www.healthline.com/health/zollinger-ellison-syndrome

  ZES is extremely rare. It occurs in only 1 in 1 million people. Its more common in men than women, and typically occurs between the ages of 30 and 50. […] If your doctor suspects ZES, they will order a blood test to check for elevated levels of gastrin. If excessive gastrin is detected, imaging tests will be performed to determine the size and location of the gastrinomas. […] Early diagnosis and treatment can help stop the spread of any cancerous tumors.

• #8 Zollinger-Ellison Syndrome – Gastrinoma | Choose the Right Test

  https://arupconsult.com/content/zollinger-ellison-syndrome

  Zollinger-Ellison syndrome (ZES) is characterized by refractory peptic ulcer disease, diarrhea, and gastric acid hypersecretion as a result of a functional pancreatic or duodenal neuroendocrine tumor (NET). ZES is also referred to as gastrinoma. […] Incidence ~1/million; gastrinoma and somatostatinomas together account for ~10% of functional pancreatic neuroendocrine tumors (PNET) (National Comprehensive Cancer Network [NCCN], 2017) […] Age diagnosis in 30s-50s […] Sex MF (slight) […] Occurrence second most common PNET.

• #9 Gastrinoma: Background, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/184332-overview

  Gastrinomas are more common in males than in females, with ratios from 1.5:1 to 2:1. […] Although rare, gastrinomas are the most common pancreatic islet cell tumors. […] The true incidence of Zollinger-Ellison syndrome (ZES) is not known. ZES constitutes 0.1% or more of the cases of peptic ulcer disease. […] In a 2013 German epidemiologic review of 2 time periods (1976-1988 and 1998-2006) comprising more than 10.8 million people, there was an approximately 5-fold increase in the cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) between 1976 and 2006, accompanied by a change in the anatomic distribution. […] Although gastrinomas can occur at any age, the initial clinical manifestation usually appears in people aged 30-50 years.

• #10 Orphanet: Zollinger-Ellison syndrome

  https://www.orpha.net/en/disease/detail/913

  Annual incidence is estimated at 1-3 cases per million. The condition is slightly more common in females than males (sex ratio of 1.3:1). […] Sporadic non-inherited ZES (75%) onset is usually in the fifth decade of life, but is 10 years earlier if part of multiple endocrine neoplasia type 1 (MEN1) (25%). […] Gastric acid hypersecretion must be controlled short- and long-term. […] In the absence of liver metastases, the prognosis is favorable (10-year survival rate of 90-100%). Patients with liver metastases (65-75%) have a 10-year survival rate of 20-40%.

• #11 ZOLLINGER-ELLISON SYNDROME. CASE REPORT

  https://www.redalyc.org/journal/5609/560962359005/html/

  The Zollinger-Ellison syndrome occurs in 0.1 to 3 people per 1 000 000 inhabitants worldwide and is predominant in women between 20 and 50 years of age. […] The exact incidence of ZES is unknown, but current literature suggests that between 0.1 and 3 people per 1 000 000 inhabitants develop the disease each year. […] Most patients are diagnosed between 20 and 50 years of age and there is a higher incidence in the female sex. […] The importance of establishing a correct diagnosis of ZES lies in the fact that it requires special treatment. Despite the wide availability of diagnostic tests, there is still a 6-9 year delay in diagnosis. ZES should be suspected in patients with peptic ulcers, ulcers distal to the duodenum, and peptic ulcer disease. […] This case report corresponds to a patient with epidemiological and clinical characteristics frequently reported in the literature, but even so, this is a clinical case that contributes to scientific knowledge as it proposes considering ZES in the differential diagnosis of patients between 20 and 50 years of age who go to the emergency department due to chronic epigastric pain.

• #12 Zollinger-Ellison syndrome epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Zollinger-Ellison_syndrome_epidemiology_and_demographics

  The incidence of gastrinoma, which can cause Zollinger-Ellison syndrome, is approximately 0.05 – 0.2 per 100,000 individuals worldwide. About 25 to 30 percent of gastrinomas are caused by multiple endocrine neoplasia type 1 (MEN1). […] The worldwide incidence of gastrinomas is about 5 to 30 cases per 100,000 individuals per year. […] Zollinger-Ellison syndrome is a disease that tends to affect the middle-aged adult population (20 – 50 years of age). […] Males are more commonly affected with Zollinger-Ellison syndrome than females. […] There is no racial predilection to Zollinger-Ellison syndrome.

• #13

  https://step2.medbullets.com/gastrointestinal/120150/zollinger-ellison-syndrome

  annual incidence is 0.5-2/million population […] high incidence in men compared to women […] Only 25% of gastrinomas arise in the pancreas with the majority occurring in the duodenum.

• #14

  https://journals.lww.com/ajg/fulltext/2024/10001/s5121_an_atypical_case_of_zollinger_ellison.5122.aspx

  Classically presenting with copious diarrhea and intractable vomiting, Zollinger-Ellison Syndrome (ZES) is defined as severe peptic ulcer disease due to gastrin-secreting neuroendocrine tumor (NET). […] Primary nodal gastrinomas may represent a significantly larger subset of cases than previously thought- accounting for up to 25% of all gastrinomas. […] EUS is a reliable way to diagnose and locally stage gastrinomas, followed by enucleation for definitive management. […] Notably, they demonstrate a lower likelihood of recurrence at approximately 5-year follow-up. […] Genetic testing for Multiple endocrine neoplasia1 syndrome should be encouraged with gastrinoma diagnosis and concomitant thymic carcinoma. […] When ZES is considered, careful analysis of lymph nodes is recommended for the possibility of primary lymph node gastrinoma.

• #15 Gastrinoma – Endocrine and Metabolic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/gastrointestinal-and-pancreatic-neuroendocrine-tumors-nets/gastrinoma

  Gastrinoma is suspected by history, particularly when symptoms are refractory to standard acid suppressant therapy. […] Once the diagnosis of gastrinoma has been established, the tumor or tumors must be localized. The first test is abdominal CT or somatostatin receptor scintigraphy, which may identify the primary tumor and metastatic disease. PET or selective arteriography with magnification and subtraction is also helpful. If no signs of metastases are present and the location of the primary tumor is uncertain, endoscopic ultrasound should be done. Selective arterial secretin injection is an alternative. […] Five- and 10-year survival are 90% when an isolated tumor is removed surgically versus 43% at 5 years and 25% at 10 years with incomplete removal (1). […] Most gastrinomas manifest with peptic ulcer symptoms, but some patients present with diarrhea. About half of patients have multiple gastrinomas, and about half have multiple endocrine neoplasia syndrome; half of gastrinomas are malignant. Serum gastrin levels are usually diagnostic, but patients with borderline elevated levels may need a secretin provocative test. Tumors can usually be localized with CT, somatostatin receptor scintigraphy, or positron emission tomography (PET). Acid secretion is suppressed with a proton pump inhibitor and sometimes also with octreotide, pending surgical removal. Newer chemotherapeutic regimens may be helpful in patients with advanced metastatic disease.

• #16 Zollinger-Ellison Syndrome – Endocrine Surgery | UCLA Health

  https://www.uclahealth.org/medical-services/surgery/endocrine-surgery/patient-resources/patient-education/endocrine-surgery-encyclopedia/zollinger-ellison-syndrome

  Zollinger-Ellison syndrome is caused by tumors usually found in the head of the pancreas and the upper small bowel. […] About one-half to two-thirds of single gastrinomas are malignant tumors that commonly spread to the liver and nearby lymph nodes. […] Nearly 25% of patients with gastrinomas have multiple tumors as part of a condition called multiple endocrine neoplasia type I (MEN I). […] Early diagnosis and surgical removal of the tumor is associated with a cure rate of only 20% to 25%. However, gastrinomas grow slowly, and patients may live for many years after the tumor is discovered.

• #17

  https://link.springer.com/article/10.1007/s11938-003-0017-6

  Zollinger-Ellison syndrome (ZES) is caused by a gastrin-producing tumor called a gastrinoma, which results in gastric acid hypersecretion. […] ZES should be suspected in patients with severe erosive or ulcerative esophagitis, multiple peptic ulcers, peptic ulcers in unusual locations, refractory peptic ulcers, complicated peptic ulcers, peptic ulcers associated with diarrhea, and a family history of multiple endocrine neoplasia type 1 (MEN-1) or any of the endocrinopathies associated with MEN-1. […] The initial diagnostic test for ZES should be a fasting serum gastrin level when antisecretory medications are discontinued. […] Somatostatin receptor scintigraphy (SRS) is the initial localization study of choice. […] In patients without metastasis and without MEN-1, surgical cure is possible in 30%.

• #17

  https://link.springer.com/article/10.1007/s11938-003-0017-6

  It has been suggested that patients with gastrinomas larger than 2.5 cm, irrespective of whether they have MEN-1, should undergo surgical resection in an effort to decrease the risk for metastasis. […] Weber CH, Venzon DJ, Lin J, et al.: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study.

• #18 Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies

  https://www.wjgnet.com/1007-9327/full/v27/i35/5890.htm

  Zollinger-Ellison syndrome (ZES) associated with pancreatic or duodenal gastrinoma is characterized by gastric acid hypersecretion, which typically leads to gastroesophageal reflux disease, recurrent peptic ulcers, and chronic diarrhea. […] The diagnosis of ZES is not always straightforward due to both non-specific symptoms and confounding factors including proton pump inhibitor (PPI) therapy, which might temporarily relieve symptoms. […] The average time between the onset of symptoms and the final diagnosis is often longer than 5 years, and nearly 25% of patients are metastatic at the first diagnosis and show a worse prognosis when compared to non-metastatic patients in whom the surgical management is associated with a promising 15-year survival rate of 80%. […] The multidisciplinary approach, with close cooperation between clinicians and surgeons, remains the cornerstone for proper management of this composite disease, which should be always referred to tertiary centers.

• #18 Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies

  https://www.wjgnet.com/1007-9327/full/v27/i35/5890.htm

  Given the high expression of STTRs in gastrinomas, gallium-68PET-scan should be always included in the diagnostic pathway of all NENs, including gastrinoma, in order to both identify the primary tumor and to stage the disease. […] The management of gastrinoma and ZES includes both a proper medical treatment for symptoms relief and surgery with curative intent whenever feasible. […] The role of surgery in the treatment of gastrinoma has changed completely from the introduction of PPIs. […] Surgical removal of the primary tumor (and possibly its metastases) with curative intent should be, indeed, always performed. […] The first step, again, is represented by syndrome control, based on PPIs, which are considered to be the drugs of choice for suppressing acid secretion.

• #19 Zollinger-Ellison Syndrome (ZES) vs. Gastrinoma

  https://www.healthline.com/health/zollinger-ellison-syndrome-vs-gastrinoma

  Zollinger-Ellison syndrome (ZES) is a health condition that results from having a gastrinoma, or gastric tumor, that increases the production of stomach acid. […] ZES refers to a group of symptoms caused by excessive gastric acid production due to a gastrinoma tumor. […] Gastrinoma can develop from a mutation in neuroendocrine cells. […] Gastrinoma is slightly more likely to develop in males than females. Theyre commonly diagnosed in people between the ages of 20 and 50. […] A doctor may order tests to diagnose you for gastrinoma if you have other health conditions that suggest the presence of a gastrin-producing tumor, such as being on PPI therapy for GERD. […] Most people diagnosed with ZES have a blood gastrin level thats extremely elevated, about 3 to 10 times the upper limit of a normal level. […] Treatment for ZES and gastrinoma typically includes medications to help manage symptoms and treatment to prevent the tumor from growing or spreading.

• #20 Zollinger-Ellison Syndrome (ZES) – Gastric Diseases – Gastrointestinal Diseases – Gastroenterology – Diseases – McMaster Textbook of Internal Medicine

  https://empendium.com/mcmtextbook/chapter/B31.II.4.70.2.

  Zollinger-Ellison syndrome (ZES) is characterized by gastrin-secreting tumors (gastrinomas), which are most frequently located in the duodenum or pancreas, rarely in adjacent lymph nodes. […] In 80% of cases the tumors are sporadic. In 20% of cases they are associated with multiple endocrine neoplasia type 1 (MEN 1). […] ZES should be suspected in the setting of multiple, refractory, or atypically distal PUD, diarrhea, or MEN 1 history. […] If the diagnosis of ZES is confirmed or highly suspected, a diagnostic workup of MEN 1 syndrome should be conducted, as 20% to 25% of patients have MEN 1.

• #21 Zollinger-Ellison Syndrome: Challenges and Management Strategies

  https://www.longdom.org/open-access/zollingerellison-syndrome-challenges-and-management-strategies-102334.html

  Zollinger-Ellison Syndrome (ZES) is a rare and chronic disorder characterized by the development of gastrin-secreting tumors called gastrinomas, typically found in the pancreas or duodenum. […] Managing ZES is a lifelong challenge for those affected, as it demands a comprehensive approach that encompasses medical, dietary, and sometimes surgical interventions. […] Regular monitoring and surveillance are essential to assess disease progression, tumor growth, and treatment effectiveness. Blood tests to measure gastrin levels, imaging studies like CT scans and MRI, and endoscopic examinations are some of the methods used for surveillance.

• #22

  http://generalsurgery.com.ua/article/view/314714

  ZollingerEllison syndrome (ZES) is a rare pathology that does not have specific clinical manifestations and is not always diagnosed in time. […] The epidemiology of the disease is highlighted. […] These patients require constant monitoring by a gastroenterologist and a surgeon and periodically undergo the necessary examinations.

• #23 Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES

  https://www.mdpi.com/2072-6694/15/5/1377

  Zollinger-Ellison syndrome (ZES) has, since its original description, been characterized by extreme acid hypersecretion due to a neuroendocrine tumor ectopically secreting gastrin, resulting in severe, recalcitrant peptic ulcer disease/gastroesophageal reflux disease (GERD) that is refractory to standard anti-acid treatments. […] From the very beginning, it became apparent that the major cause of the acute- and long-term morbidity and mortality in these patients was not the gastrinomas, which were malignant in a majority of cases and generally slow-growing, but instead the presence of uncontrolled gastric acid hypersecretion. […] There are several important current controversies in the treatment of ZES, but one central issue to the management of all ZES patients is that the acid hypersecretion needs to be controlled at all times and it is unclear whether this is feasible long-term (>5 years).

• #23 Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES

  https://www.mdpi.com/2072-6694/15/5/1377

  This uncertainty occurs for a number of reasons. First, only 5–20% of ZES patients are surgically curable by complete resection of the gastrinoma. […] The uncertainty is also primarily due to the lack of data from any long-term/lifetime treatment studies of acid antisecretory control in ZES patients. […] The current study aimed to address these issues. The NIH prospective study on all aspects of ZES has been in effect since 1974, and part of the study involves the long-term medical management of the acid hypersecretion of all patients. […] Our results demonstrate long-term/lifetime treatment of acid hypersecretion is possible in all patients with each class of acid antisecretory drug; however, PPIs are preferable because of their greater potency and long duration of action. […] The most important conclusion of the present study is that long-term/lifelong medical treatment of acid hypersecretion in ZES patients is possible and can be successful in controlling peptic acid symptoms and preventing the development of acid-related complications in all patients.

• #24 Gastric Neuroendocrine Tumors | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/31473

  GNETs are rare but increasingly recognized neoplasms, with an estimated incidence of 0.2 to 2 per 100,000 people annually. Their prevalence has risen due to increased endoscopic surveillance and improved histopathologic detection. […] Type 2 GNETs develop in association with ZES, often in the context of MEN1. In these cases, excessive gastrin production from gastrinoma results in ECL cell proliferation and tumor formation, although the presence of MEN1 mutations also contributes to their pathogenesis. […] Type 2 GNETs, accounting for about 5% to 6% of cases, occur equally in both sexes and are associated with ZES, particularly in patients with MEN1. […] In contrast, type 3 tumors exhibit aggressive behavior with a poorer prognosis, often presenting with distant metastases at diagnosis. […] Globally, GNETs have shown a rising incidence, with reports suggesting an increase in the number of diagnosed cases in Europe and Asia, particularly in countries with widespread gastric cancer screening programs.

• #25 Zollinger Ellison Syndrome – Epidemiology Forecast – 2032

  https://www.researchandmarkets.com/reports/5525526/zollinger-ellison-syndrome-epidemiology?srsltid=AfmBOop9KcefyAkaCKYjEVxcIHg7UfPTLocEo4r2L5uxsnLkmbJgqHvv

  This „Zollinger Ellison Syndrome – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Zollinger Ellison Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] The Zollinger Ellison Syndrome epidemiology report gives a thorough understanding of the Zollinger Ellison Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Zollinger Ellison Syndrome in the US, Europe, and Japan. The report covers the detailed information of the Zollinger Ellison Syndrome epidemiology scenario in seven major countries (US, EU5, and Japan). […] The Zollinger Ellison Syndrome epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Zollinger Ellison Syndrome epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Zollinger Ellison Syndrome epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

• #25 Zollinger Ellison Syndrome – Epidemiology Forecast – 2032

  https://www.researchandmarkets.com/reports/5525526/zollinger-ellison-syndrome-epidemiology?srsltid=AfmBOop9KcefyAkaCKYjEVxcIHg7UfPTLocEo4r2L5uxsnLkmbJgqHvv

  The Zollinger Ellison Syndrome epidemiology covered in the report provides historical as well as forecasted Zollinger Ellison Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032. The Zollinger Ellison Syndrome report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight. […] The Zollinger Ellison Syndrome Epidemiology Report and Model provide an overview of the global trends of Zollinger Ellison Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

• #25 Zollinger Ellison Syndrome – Epidemiology Forecast – 2032

  https://www.researchandmarkets.com/reports/5525526/zollinger-ellison-syndrome-epidemiology?srsltid=AfmBOop9KcefyAkaCKYjEVxcIHg7UfPTLocEo4r2L5uxsnLkmbJgqHvv

  The report provides insight into the historical and forecasted patient pool of Zollinger Ellison Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan. […] The report assesses the disease risk and burden and highlights the unmet needs of Zollinger Ellison Syndrome.

• #26 Gastrinoma – Wikipedia

  https://en.wikipedia.org/wiki/Gastrinoma

  Gastrinoma is the second most common functional pancreatic neuroendocrine tumor (pNET), with a yearly incidence of approximately 0.5 to 21.5 cases per a million of people worldwide. Gastrinomas are located predominantly in the duodenum (70%) and pancreas (25%). Pancreatic gastrinomas are larger than their duodenal counterparts, may occur in any portion of the pancreas, and comprise 25% of these tumors. Gastrinomas are also the most common functional and malignant pancreatic endocrine tumors. They are characterized by gastric hypersecretion that results in peptic ulcers and diarrhea; this condition is known as ZollingerEllison syndrome (ZES). […] Recently, research studies have been conducted to seek new medical advances in relation to gastrinoma and ZollingerEllison syndrome. The recent studies have shown improved understanding of pathogenesis of pancreatic neuroendocrine tumors, classifications of those tumors, new treatments/preventions to control the gastrin levels in the gastrointestinal tract, and the best and safest surgical approaches.

• #27 Zollinger-Ellison Syndrome Treatment Market – Global Market – Industry Trends and Forecast to 2030 | Data Bridge Market Research

  https://www.databridgemarketresearch.com/reports/global-zollinger-ellison-syndrome-treatment-market?srsltid=AfmBOor_RaqUuH2NZkjlv_0BZVUEk5j7KB-mQhyncWe6aTAPYF_1ylhz

  Zollinger-Ellison syndrome is present in 0.5 to 3 out of every 1 million persons yearly. […] The disorder is characteristically diagnosed in patients between the ages of 20 and 50 years. […] Around 80% of cases of Zollinger-Ellison syndrome are distinct to any other illnesses; though, 20 to 25% of incidences are in patients with multiple endocrine neoplasia type 1, which is a rare genetic abnormality. […] Data Bridge Market Research analyses a growth rate in the zollinger-ellison syndrome treatment market in the forecast period 2023-2030. […] The expected CAGR of zollinger-ellison syndrome treatment market is tend to be around 4.50% in the mentioned forecast period. […] The market was valued at USD 1.3 billion in 2022, and it would grow up to USD 1.85 billion by 2030. […] The current growing research organizations in the market are armed with and utilize the knowledge of professionals in several clinical disciplines, that lead to major advances in understanding zollinger-ellison syndrome treatment.

• #27 Zollinger-Ellison Syndrome Treatment Market – Global Market – Industry Trends and Forecast to 2030 | Data Bridge Market Research

  https://www.databridgemarketresearch.com/reports/global-zollinger-ellison-syndrome-treatment-market?srsltid=AfmBOor_RaqUuH2NZkjlv_0BZVUEk5j7KB-mQhyncWe6aTAPYF_1ylhz

  The market growth is boosted by an increase in the number of RD activities. […] The government is funding RD initiatives to encourage researchers and pharmaceutical companies to develop advanced medicines. […] North America is dominating the market in the forecast period due to the presence of key product manufacturers and increasing research and development activities. […] Asia-Pacific is considered to grow over the coming years due to increased new research and developments on zollinger-ellison syndrome treatment market.

• #28 Zollinger-Ellison Syndrome: Symptoms, Causes, Diagnosis & Treatment | Medanta

  https://www.medanta.org/hospitals-near-me/gurugram-hospital/speciality/gi-surgery/disease/zollinger-ellison-syndrome-symptoms-causes-treatment-diagnosis

  Some of the risk factors for ZES include having a family history of the condition or multiple endocrine neoplasia type 1 (MEN1), a genetic disorder that can cause tumours in various endocrine glands, including the pancreas. […] One of the key ways to prevent ZES is to identify and address the underlying medical conditions or risk factors that can contribute to the development of this syndrome. […] Regular check-ups with a healthcare provider can also help to prevent ZES. […] The Zollinger-Ellison Syndrome diagnosis (ZES) begins with a comprehensive evaluation of a patient’s medical history and symptoms. […] To confirm a diagnosis of ZES, a healthcare provider may order several tests, including blood tests, imaging studies, and endoscopic examinations. […] The treatment and Zollinger Ellison Syndrome management depends on the stage of the condition and the severity of the symptoms. The primary aim of treatment of Zollinger Ellison Syndrome is to curb the production of stomach acid and control the symptoms of ZES. […] Individuals with Zollinger-Ellison Syndrome should be monitored regularly through imaging and blood tests to monitor tumour growth and ensure proper treatment.

• #29

  https://journals.lww.com/jiap/fulltext/2017/22030/zollinger_ellison_syndrome_in_a_12_year_old_child.10.aspx

  The overall incidence of ZollingerEllison syndrome is 0.13/million and among these patients, only 2% belong to the pediatric population. […] Gastrinoma should be suspected in children of refractory peptic ulcer disease. Gastric mucosal thickness on ultrasound or CT scan can serve as a good corroborative diagnostic as well as follow-up modality in these patients. […] Hence, regular follow-up and surveillance of these patients are mandatory.

• #30 Zollinger-Ellison Syndrome | 5-Minute Clinical Consult

  https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688838/all/Zollinger_Ellison_Syndrome

  1 to 3 per million per year in the United States. […] Predominant age: middle age (30 to 65 years). Mean age of onset is 43 years; presents a decade earlier in patients with ZES/MEN1. […] Predominant sex: male female (1.3:1). […] Aggressive cases have been reported in teenagers. […] Rare, pregnancy alters medication choices and surgical timing.

Zobacz więcej